Locteron (interferon alpha-2b CR)
/ Dr. Reddy’s, Biolex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 07, 2012
Biolex sells LEX system to Synthon and initiates sale of Locteron
(Market Watch)
- Biolex has initiated the sale of its remaining P3 ready asset, Locteron for the treatment of HCV; In P2b clinical trials in HCV Locteron demonstrated statistically significant reductions in flu-like symptoms, reduced rates of depression, and cutting in half the number of injections required compared to pegylated interferon.
Sales update • Hepatitis C Virus
1 to 1
Of
1
Go to page
1